NCT07365514 Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
| NCT ID | NCT07365514 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Connecticut |
| Condition | Postmenopausal Osteoporosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 159 participants |
| Start Date | 2026-07 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 159 participants in total. It began in 2026-07 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.
Eligibility Criteria
Inclusion Criteria: * postmenopausal (defined as no more than 10 years since final menstrual cycle) females aged 45-70 years * not on hormone replacement therapy for at least one year before initiation of the study * maintaining normal exercise level (\< 7 hours/week) and willing to avoid exercise for 24 hours prior to blood and stool sampling * willing to ingest a dietary blackcurrant supplement or placebo (up to 1,176 mg/day, three 392mg capsules) * willing to avoid other dietary supplements for the duration of the study * willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli * willing to have three blood draws, three stool collections, and three bone scans Exclusion Criteria: * history of cardiovascular disease, osteoporosis, metabolic bone disease, cancer, diabetes mellitus, arthritis, or other chronic inflammatory diseases * current smokers * taking prescription medications known to alter bone and calcium metabolism * taking anabolic agents such as parathyroid hormone or growth hormone, or steroid within 3 months before the start of the study * taking medications that alter bleeding (such as antiplatelets or anticoagulants) or those with a bleeding disorder * alcohol consumption exceeding 2 drinks/day (approximately 14g of ethanol per drink) or a total of 12/week * those with planned surgery during the study period or within 2 weeks of ending the intervention * those with sensitivities or allergies to any of the ingredients for the placebo (rice powder) * planning a procedure that includes iodine, barium or nuclear medicine isotopes within the study period * UConn students and/or employees who any key personnel teach or who report to any key personnel * study key personnel, partners of key personnel, or dependents/relatives of any key personnel
Contact & Investigator
Ock Chun, PhD
PRINCIPAL INVESTIGATOR
University of Connecticut
Frequently Asked Questions
Who can join the NCT07365514 clinical trial?
This trial is open to female participants only, aged 45 Years or older, up to 70 Years, studying Postmenopausal Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07365514 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07365514 currently recruiting?
Yes, NCT07365514 is actively recruiting participants. Contact the research team at ock.chun@uconn.edu for enrollment information.
Where is the NCT07365514 trial being conducted?
This trial is being conducted at Storrs, United States.
Who is sponsoring the NCT07365514 clinical trial?
NCT07365514 is sponsored by University of Connecticut. The principal investigator is Ock Chun, PhD at University of Connecticut. The trial plans to enroll 159 participants.